Triethylamine → 1-((1R,5S)-8-{2-[4-(2,2-dimethylpropanoyl)-2-phenylmorpholin-2-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole

HRID 272004Notes

Reaction equation

HRID 272004 reaction equation
Cl.Cl.Cl.[CH3:4][C:5]1[N:9]([CH:10]2[CH2:16][C@H:15]3[N:17]([CH2:18][CH2:19][C:20]4([C:26]5[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=5)[O:25][CH2:24][CH2:23][NH:22][CH2:21]4)[C@H:12]([CH2:13][CH2:14]3)[CH2:11]2)[C:8]2[CH:32]=[CH:33][CH:34]=[CH:35][C:7]=2[N:6]=1.CCN(CC)CC.[CH3:43][C:44]([CH3:49])([CH3:48])[C:45](Cl)=[O:46]>C(Cl)Cl>[CH3:43][C:44]([CH3:49])([CH3:48])[C:45]([N:22]1[CH2:23][CH2:24][O:25][C:20]([CH2:19][CH2:18][N:17]2[C@H:12]3[CH2:13][CH2:14][C@@H:15]2[CH2:16][CH:10]([N:9]2[C:8]4[CH:32]=[CH:33][CH:34]=[CH:35][C:7]=4[N:6]=[C:5]2[CH3:4])[CH2:11]3)([C:26]2[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=2)[CH2:21]1)=[O:46]

Participants

5

Procedure

To a solution of 2-methyl-1-{(1R,5S)-8-[2-(2-phenylmorpholin-2-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole trihyrdochloride (65 mg, 0.11 mmol) and Et3N (0.08 mL, 0.55 mmol in 1 mL CH2Cl2 was added trimethylacetyl chloride (0.02 mL, 0.17 mmol), and the reaction was stirred for 24 h. After washing with saturated aqueous NaHCO3, the organic phase was isolated, dried (Na2SO4), concentrated and chromatographed (5% (2M NH3/MeOH) in CHCl3) to afford 1-((1R,5S)-8-{2-[4-(2,2-dimethylpropanoyl)-2-phenylmorpholin-2-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (61 mg, quant.) as a film: 1H NMR (400 MHz, CDCl3), δ 7.68 (m, 1H), 7.45-7.40 (m, 2H), 7.38-7.27 (m, 3H), 7.19-7.11 (m, 2H), 4.77-4.63 (m, 2H), 3.76-3.54 (m, 4H), 3.40-3.20 (m, 3H), 2.59 (s, 3H), 2.48-2.36 (m, 2H), 2.15-1.85 (m, 8H), 1.69-1.59 (m, 2H), 1.19 (s, 9H); ESI-MS 515 (M+H).

Workup

  1. washAfter washing with saturated aqueous NaHCO3
  2. customthe organic phase was isolated
  3. dry with materialdried (Na2SO4)
  4. concentrationconcentrated
  5. customchromatographed (5% (2M NH3/MeOH) in CHCl3)

Sources & evidence

ORD record
ord-e9ae0128fd274a21afd294e3314143ce
Source dataset
uspto-grants-2008_11
Patent number
US07452992B2

Reaction notes

Loading…